WO2005023302A3 - Anti-cd20 therapy of ocular disorders - Google Patents

Anti-cd20 therapy of ocular disorders Download PDF

Info

Publication number
WO2005023302A3
WO2005023302A3 PCT/US2004/027164 US2004027164W WO2005023302A3 WO 2005023302 A3 WO2005023302 A3 WO 2005023302A3 US 2004027164 W US2004027164 W US 2004027164W WO 2005023302 A3 WO2005023302 A3 WO 2005023302A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
ocular disorders
ocular
disorders
antagonists
Prior art date
Application number
PCT/US2004/027164
Other languages
French (fr)
Other versions
WO2005023302A2 (en
Inventor
Paul G Brunetta
Original Assignee
Genentech Inc
Paul G Brunetta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Paul G Brunetta filed Critical Genentech Inc
Priority to JP2006524757A priority Critical patent/JP2007504138A/en
Priority to AU2004270165A priority patent/AU2004270165A1/en
Priority to MXPA06002134A priority patent/MXPA06002134A/en
Priority to BRPI0412629-7A priority patent/BRPI0412629A/en
Priority to CA002535895A priority patent/CA2535895A1/en
Priority to EP04781779A priority patent/EP1660129A2/en
Publication of WO2005023302A2 publication Critical patent/WO2005023302A2/en
Publication of WO2005023302A3 publication Critical patent/WO2005023302A3/en
Priority to IL173351A priority patent/IL173351A0/en
Priority to NO20061412A priority patent/NO20061412L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present application describes therapy of ocular disorders using antagonists, such as antibodies, that bind to CD20.
PCT/US2004/027164 2003-08-29 2004-08-20 Anti-cd20 therapy of ocular disorders WO2005023302A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2006524757A JP2007504138A (en) 2003-08-29 2004-08-20 Treatment of eye diseases
AU2004270165A AU2004270165A1 (en) 2003-08-29 2004-08-20 Anti-CD20 therapy of ocular disorders
MXPA06002134A MXPA06002134A (en) 2003-08-29 2004-08-20 Anti-cd20 therapy of ocular disorders.
BRPI0412629-7A BRPI0412629A (en) 2003-08-29 2004-08-20 Method of treating eye dysfunction in mammals
CA002535895A CA2535895A1 (en) 2003-08-29 2004-08-20 Anti-cd20 therapy of ocular disorders
EP04781779A EP1660129A2 (en) 2003-08-29 2004-08-20 Anti-cd20 therapy of ocular disorders
IL173351A IL173351A0 (en) 2003-08-29 2006-01-25 Therapy of ocular disorders
NO20061412A NO20061412L (en) 2003-08-29 2006-03-28 Therapy of ocular disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49879103P 2003-08-29 2003-08-29
US60/498,791 2003-08-29

Publications (2)

Publication Number Publication Date
WO2005023302A2 WO2005023302A2 (en) 2005-03-17
WO2005023302A3 true WO2005023302A3 (en) 2005-04-28

Family

ID=34272728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027164 WO2005023302A2 (en) 2003-08-29 2004-08-20 Anti-cd20 therapy of ocular disorders

Country Status (14)

Country Link
US (2) US20050053602A1 (en)
EP (1) EP1660129A2 (en)
JP (1) JP2007504138A (en)
KR (1) KR20060132554A (en)
CN (1) CN1845755A (en)
AU (1) AU2004270165A1 (en)
BR (1) BRPI0412629A (en)
CA (1) CA2535895A1 (en)
IL (1) IL173351A0 (en)
MX (1) MXPA06002134A (en)
NO (1) NO20061412L (en)
RU (1) RU2006110036A (en)
WO (1) WO2005023302A2 (en)
ZA (1) ZA200601218B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (en) 1999-05-07 2002-07-02 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers.
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
KR101351122B1 (en) * 2003-05-09 2014-01-14 듀크 유니버시티 CD20-Specific Antibodies and Methods of Employing Same
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
SV2006002131A (en) * 2004-06-04 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF LUPUS
CN1993143A (en) * 2004-06-04 2007-07-04 健泰科生物技术公司 Method for treating multiple sclerosis
RU2007106722A (en) * 2004-07-22 2008-08-27 Дженентек, Инк. (Us) METHOD FOR TREATING SHEHREN'S SYNDROME
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc TREATMENT OF INTESTINAL INFLAMMATORY DISEASE (IBD)
BRPI0613259A2 (en) * 2005-05-20 2010-12-28 Genentech Inc biological sample treatment method and diagnostic kit
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
TW201438738A (en) * 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
RS60739B1 (en) 2014-11-17 2020-09-30 Regeneron Pharma Methods for tumor treatment using cd3xcd20 bispecific antibody
CN112771077A (en) 2018-08-31 2021-05-07 瑞泽恩制药公司 Dosing strategy for reducing cytokine release syndrome for CD3/C20 bispecific antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003734A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
JP3095175B2 (en) * 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
NZ573838A (en) * 1998-08-11 2011-01-28 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
JP4286483B2 (en) * 1999-06-09 2009-07-01 イムノメディクス， インコーポレイテッド Immunotherapy for autoimmune diseases using antibodies targeting B cells
DE19930748C2 (en) * 1999-07-02 2001-05-17 Infineon Technologies Ag Method for producing EEPROM and DRAM trench memory cell areas on a chip
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004500412A (en) * 2000-03-31 2004-01-08 アイデック　ファーマスーティカルズ　コーポレイション Combination of anti-cytokine antibody or antagonist and anti-CD20 for treatment of B-cell lymphoma
CN101289511A (en) * 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
SI1296714T1 (en) * 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP4679035B2 (en) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド Combination therapy
US7785819B2 (en) * 2001-04-10 2010-08-31 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
DE60233744D1 (en) * 2001-09-20 2009-10-29 Univ Texas DETERMINATION OF CIRCULATING THERAPEUTIC ANTIBODIES, ANTIGENS AND ANTIGEN-ANTIBODY COMPLEXES WITH ELISA TESTS
KR100988949B1 (en) * 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003734A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor

Also Published As

Publication number Publication date
IL173351A0 (en) 2006-06-11
NO20061412L (en) 2006-03-28
EP1660129A2 (en) 2006-05-31
MXPA06002134A (en) 2006-05-31
ZA200601218B (en) 2007-05-30
RU2006110036A (en) 2006-08-10
US20090136492A1 (en) 2009-05-28
AU2004270165A1 (en) 2005-03-17
BRPI0412629A (en) 2006-09-26
US20050053602A1 (en) 2005-03-10
JP2007504138A (en) 2007-03-01
CN1845755A (en) 2006-10-11
KR20060132554A (en) 2006-12-21
CA2535895A1 (en) 2005-03-17
WO2005023302A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
HRP20181459T1 (en) Humanized anti-beta7 antagonists and uses thererfor
IL245462A0 (en) Humanized anti-cmet antagonists
WO2005099756A3 (en) ErbB ANTAGONISTS FOR PAIN THERAPY
WO2006085967A3 (en) OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2005097832A3 (en) Humanized anti-tgf-beta antibodies
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2009008104A (en) Hepcidin, hepcidin antagonists and methods of use.
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2007033140A3 (en) Prok2 antagonists and methods of use
WO2007038407A3 (en) Compositions and methods for treating nervous system disorders
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024982.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 390/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004270165

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 545029

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006/01218

Country of ref document: ZA

Ref document number: 200601218

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2535895

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004270165

Country of ref document: AU

Date of ref document: 20040820

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004270165

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002134

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020067003992

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006524757

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004781779

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006110036

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004781779

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412629

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067003992

Country of ref document: KR